Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases.
Industry: Health Care
Latest Trade: $7.99 0.00 (0.0%)
First Day Return: -16.9%
Return from IPO: -50.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 06/07/2024 |
Offer Price | $16.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 13.1 |
Deal Size ($mm) | $210 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 06/27/2024 |
Offer Price | $16.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 13.1 |
Deal Size ($mm) | $210 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Morgan Stanley |
Leerink Partners |
more |
Company Data | |
---|---|
Headquarters | South San Francisco, CA, United States |
Founded | 2021 |
Employees at IPO | 109 |
Website www.alumis.com |